Skip to main content

Table 2 Patient and tumour characteristic by group of treatment

From: Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer

  CT-RT RT-EGFRinhibitors  
Patient/Tumour Data No. % No. % p
Nº of patients 56 52  
Age, years    
   Median 58 60 NS
   Range 44-74 33-84  
Sex      
   Male 55 98 46 89 0.05
   Female 1 2 6 11  
Current smokers      
   No 3 5 3 6 NS
   Yes 28 50 49 94  
   Unknown 25 45 0 0  
Alcohol consumption      
   No 1 2 12 23  
   Yes 28 50 39 75 0.02
Unknown 27 48 1 2  
Performance status      
   ECOG 0–1 51 91 45 87 NS
   ECOG 2-3 5 9 7 13  
Tumor site      
   Oral cavity 13 23 3 6  
Oropharynx 16 29 23 44 0.02
   Larynx 17 30 21 40  
   Hypopharynx 10 18 5 10  
Grade      
   Well/Moderate 34 61 12 23 NS
   Poor 5 9 6 12  
   Unknown 17 30 34 65  
Tumour stage      
   T1-T3 20 36 30 58 NS
   T4 36 64 22 42  
Nodal status      
   N0-N1 24 43 32 61 NS
   N2-N3 32 57 20 39  
P16 expression      
negative 46 82 44 85 NS
positive 10 18 8 15  
HPV16 expression      
negative 50 89 46 88 NS
positive 6 11 6 12  
Irradiation dose 71.2   71   NS
Mean 57-72   70-78   
Range      
Type of radiotherapy      
Conventional RT 1 2 10 19 0.003
Concomitant boost 55 92 42 81  
Response      
Complete response 42 75 41 79  
Partial response 8 14 8 15 NS
Stable disease 2 4 0 0  
Progression 1 2 0 0  
Unknown 3 5 3 6